Holen Sie sich die Stockscreener-App
19.70
2.44%
0.47
Handel nachbörslich:
19.70
Schlusskurs vom Vortag:
$19.23
Offen:
$19.45
24-Stunden-Volumen:
159.47K
Relative Volume:
0.93
Marktkapitalisierung:
$172.47M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-985.00
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
-1.94%
1M Leistung:
+23.82%
6M Leistung:
+48.50%
1J Leistung:
+17.84%
1-Tages-Spanne:
$19.20
$20.19
1-Wochen-Bereich:
$18.54
$20.25
52-Wochen-Spanne:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
19.70 | 168.35M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Seres Therapeutics (MCRB) to Present New Phase 1b Trial Data at IDWeek 2025 - GuruFocus
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - The Manila Times
Seres Therapeutics Presents 77% BSI Reduction in SER-155 Phase 1b | MCRB Stock News - Stock Titan
Is Seres Therapeutics Inc. stock a contrarian buyAnalyst Downgrade & Expert Curated Trade Setups - newser.com
How Seres Therapeutics Inc. (1S90) stock moves on employment dataMarket Performance Recap & Stock Timing and Entry Methods - newser.com
News impact scoring models applied to Seres Therapeutics Inc.CPI Data & Fast Gaining Stock Strategy Reports - newser.com
Vontobel Holding Ltd. Has $892,000 Holdings in Seres Therapeutics, Inc. $MCRB - MarketBeat
Will Seres Therapeutics Inc. stock benefit from infrastructure spendingMarket Performance Report & High Accuracy Trade Alerts - newser.com
Is Seres Therapeutics Inc. stock supported by innovation pipelineMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Seres Therapeutics soars on report of takeover offer - MSN
Exit strategy if you’re trapped in Seres Therapeutics Inc.Weekly Trading Summary & Expert Verified Movement Alerts - newser.com
Is Seres Therapeutics Inc. forming a bottoming baseTreasury Yields & Long-Term Growth Plans - newser.com
Can you recover from losses in Seres Therapeutics Inc.Weekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com
Quantitative breakdown of Seres Therapeutics Inc. recent moveCPI Data & Stepwise Swing Trade Plans - newser.com
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Is it too late to sell Seres Therapeutics Inc.2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Seres Therapeutics (NASDAQ:MCRB) Receives "Sell (D+)" Rating from Weiss Ratings - MarketBeat
Building trade automation scripts for Seres Therapeutics Inc.July 2025 Macro Moves & High Return Trade Opportunity Guides - newser.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Target Price at $14.33 - Defense World
Technical signs of recovery in Seres Therapeutics Inc.July 2025 Trends & Verified Momentum Watchlists - newser.com
Seres Therapeutics Inc. stock retracement – recovery analysisMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com
How high can Seres Therapeutics Inc. stock goMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Published on: 2025-10-05 04:28:16 - newser.com
Understanding Seres Therapeutics Inc.’s price movementJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Seres Therapeutics Inc. a candidate for recovery playJuly 2025 Update & Daily Entry Point Alerts - newser.com
Seres Therapeutics announces workforce reduction to extend cash runway - Investing.com
Seres Therapeutics Cuts Costs to Extend Cash Runway - TipRanks
Dated alerts on Seres Therapeutics' measures to cut costs withdrawn - MarketScreener
Developing predictive dashboards with Seres Therapeutics Inc. dataWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com
Using data tools to time your Seres Therapeutics Inc. exit2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-03 00:05:20 - newser.com
Is Seres Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Outperform the Market with Aggressive Picks - earlytimes.in
Goldman Sachs Group Inc. Acquires 21,679 Shares of Seres Therapeutics, Inc. $MCRB - MarketBeat
What analysts say about Seres Therapeutics Inc stockInstitutional Holding Changes & Capitalize On Fast Trends - earlytimes.in
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):